Health ❯ Obesity

Treatment Options

Medications Pharmaceuticals Weight Loss Drugs Medication Injectable Medications Oral Medications Clinical Trials GLP-1 Agonists Pharmaceutical Innovations GLP-1 Drugs Pharmaceutical Treatments Drug Efficacy GLP-1 Medications Weight Loss Injections Drug Development Semaglutide Drug Combinations GLP-1 Receptor Agonists Regulatory Issues Orforglipron Patient Preferences Medication Risks Gene Therapy Surgical Procedures GLP-1 Therapies Drug Candidates Drug Mechanisms Drug Delivery Systems Diabetes Management Medications for Obesity Lifestyle Changes Drug Therapies Clinical Studies Incretin Medications Patient Access Non-Invasive Procedures Weight Loss Strategies Weight-loss Injections Prescription Drugs Weight-Loss Drugs Hormonal Treatments Surgery vs. Medication Telehealth Services Pharmacy Services Medical Interventions Prescription Medications NHS Clinical Development

FDA Approves Wegovy Weight-Loss Pill as First Oral GLP-1 for Obesity

A $149 starter offer alongside a January U.S. launch positions the daily tablet to broaden access.

Stories older than 24h

GLP-1 Drugs Are Changing What Households Buy, Study Finds

Pfizer Licenses Early-Stage Oral GLP-1 From YaoPharma in Up to $2 Billion Deal

Structure Therapeutics' Oral GLP-1 Posts Up to 15% Placebo-Adjusted Weight Loss as Company Prepares Phase 3

Eli Lilly Becomes First Health Care Company Valued at $1 Trillion

Pfizer Closes Metsera Buyout, Adding GLP-1 Assets in Cash-Plus-CVR Deal

Novo Nordisk Slashes Wegovy Price in India by Up to 37% to Take On Mounjaro

Pfizer Clinches $10 Billion Metsera Deal After Novo Nordisk Withdraws

Pfizer Wins Early U.S. Antitrust Clearance for Metsera Deal as Novo’s Higher Bid Pressures Timeline

Novo Nordisk Survey Finds Wegovy Users Report Sharp Drop in ‘Food Noise’

Novo Nordisk Freezes Hiring as Layoffs Loom in GLP-1 Retrenchment

Lilly’s Oral GLP-1 Pill Underperforms Wegovy in Late-Stage Trial

GLP-1 Weight-Loss Drugs Fail to Boost Fitness and Cause Significant Muscle Loss

Hims & Hers Plans Canadian Launch of Generic Semaglutide After Zava Acquisition

Amgen Advances Monthly Obesity Drug to Phase 3 After 20% Weight Loss in Mid-Stage Trial

Bariatric Surgery Surpasses GLP-1 Drugs in Real-World Weight Loss